Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 25

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 25
---
 capital, total stockholders’ equity and total capitalization by approximately $0.7 million ($0.7 million), assuming no change in the public offering price per share of Common Stock and accompanying common warrant, and after deducting estimated Placement Agent fees and estimated offering expenses payable by us.

The discussion and table above are
based on 14,620,732 shares outstanding as of March 31, 2025 and excludes the following:

| ● | 1,942,351                                                                                                                 
 shares of Common Stock issuable upon the exercise                                                                         
 of outstanding stock options as of March 31, 2025, having a weighted average exercise price of $1.78 per share;           |
| ● | 39,700                                                                                                                    
 shares of Common Stock issuable upon the vesting of Common Stock awards as of March 31, 2025, having a weighted average   
 grant date fair value of $0.99 per share;                                                                                 |
| ● | 5,155,060                                                                                                                 
 shares of Common Stock issuable upon the exercise of outstanding warrants as of March 31, 2025, having a weighted average 
 exercise price of $2.51 per share; and                                                                                    |
| ● | 223,522                                                                                                                   
 shares of Common Stock reserved for future issuance                                                                       
 pursuant to our existing stock incentive plan.                                                                            |

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

| 10 |

<div align='center'>DILUTION</div>

If you purchase securities in this offering, assuming no sale of any pre-funded warrants and no exercise of the common warrants issued in connection with this offering, your ownership interest will be immediately diluted to the extent of the difference between the combined public offering price per share of our Common Stock and accompanying warrant in this offering and the pro forma as adjusted net tangible book value per share of our Common Stock immediately after giving effect to this offering.

Our net tangible book value as of March 31, 2025 was approximately $0.5 million, or approximately $0.03 per share of our Common Stock. Our net tangible book value is the amount of our total tangible assets minus total liabilities. Net tangible book value per share as of March 31, 2025 is our net tangible book value divided by the number of shares of Common Stock outstanding as of March 31, 2025.

Our pro forma net tangible book value as of March 31,